Abstract
Almost 200 million people worldwide are found to be affected by Diabetes mellitus (DM). DM is a metabolic disorder which occurs due to reduced insulin action and/or insulin secretion in the body. Reduced or inactive insulin results in imbalanced food metabolism. With the progression of disease, pathological changes like nephropathy, retinopathy and cardiovascular complications start occurring in the body. DM is mainly categorized into 2 types: type 1 DM and type 2 DM. Type 1 is generally treated through insulin replacement therapy. Type 2 DM is treated with oral hypoglycemics. Oral hypoglycemics are classified into 5 types: sulfonylureas, biguanides, α-glucosidase inhibitors, meglitinide analogues and thiazolidinediones. Conventional dosage forms of most of these drugs bear some drawbacks such as frequent dosing, short half live, and low bioavailability. Therefore, to alleviate the drawbacks associated with conventional dosage forms, efforts have been made in the area of novel and controlled drug delivery system for oral hypoglycemics. Present review highlights various novel and controlled drug delivery systems that have been investigated by different researchers for achieving sustained and controlled drug delivery of oral hypoglycemics and for overcoming the limitations related with the conventional dosage forms of oral hypoglycemics.
Keywords: Diabetics, Oral hypoglycemics, Conventional therapy, Novel Drug Delivery Systems, Sustained release, Marketed formulations.
Current Drug Delivery
Title:Recent Advances in Drug Delivery Systems for Anti-Diabetic Drugs: A Review
Volume: 11 Issue: 4
Author(s): Meenu Grover and Puneet Utreja
Affiliation:
Keywords: Diabetics, Oral hypoglycemics, Conventional therapy, Novel Drug Delivery Systems, Sustained release, Marketed formulations.
Abstract: Almost 200 million people worldwide are found to be affected by Diabetes mellitus (DM). DM is a metabolic disorder which occurs due to reduced insulin action and/or insulin secretion in the body. Reduced or inactive insulin results in imbalanced food metabolism. With the progression of disease, pathological changes like nephropathy, retinopathy and cardiovascular complications start occurring in the body. DM is mainly categorized into 2 types: type 1 DM and type 2 DM. Type 1 is generally treated through insulin replacement therapy. Type 2 DM is treated with oral hypoglycemics. Oral hypoglycemics are classified into 5 types: sulfonylureas, biguanides, α-glucosidase inhibitors, meglitinide analogues and thiazolidinediones. Conventional dosage forms of most of these drugs bear some drawbacks such as frequent dosing, short half live, and low bioavailability. Therefore, to alleviate the drawbacks associated with conventional dosage forms, efforts have been made in the area of novel and controlled drug delivery system for oral hypoglycemics. Present review highlights various novel and controlled drug delivery systems that have been investigated by different researchers for achieving sustained and controlled drug delivery of oral hypoglycemics and for overcoming the limitations related with the conventional dosage forms of oral hypoglycemics.
Export Options
About this article
Cite this article as:
Grover Meenu and Utreja Puneet, Recent Advances in Drug Delivery Systems for Anti-Diabetic Drugs: A Review, Current Drug Delivery 2014; 11 (4) . https://dx.doi.org/10.2174/1567201811666140118225021
DOI https://dx.doi.org/10.2174/1567201811666140118225021 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
GABAergic Modulation in Diabetic Encephalopathy-Related Depression
Current Pharmaceutical Design Aldose Reductase in Diabetic Microvascular Complications
Current Drug Targets Hypertension in Pregnancy: Pathophysiology & Management Strategies
Current Pharmaceutical Design Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes
CNS & Neurological Disorders - Drug Targets Recent Advances in Cell Sheet Technology for Periodontal Regeneration
Current Stem Cell Research & Therapy Animal Models of Lupus and Lupus Nephritis
Current Pharmaceutical Design Prevalence and Related Factors of Sarcopenia in Community-dwelling Elderly with Long-term Care Insurance
Reviews on Recent Clinical Trials The Hypothalamic-Neurohypophyseal System: Current and Future Treatment of Vasopressin and Oxytocyn Related Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Predictive Factors of follow-up Non-attendance and Mortality Among Adults with Type 2 Diabetes Mellitus- an Analysis of the Malaysian Diabetes Registry 2009
Current Diabetes Reviews Cell Hierarchy, Metabolic Flexibility and Systems Approaches to Cancer Treatment
Current Pharmaceutical Biotechnology Effects of Exercise Training on Delaying Disease Progression in Patients with Chronic Kidney Disease: a Review of the Literature
Reviews on Recent Clinical Trials Risk Factors for Heart Failure Progression and Outcomes
Current Cardiology Reviews Regulation of the DNA Damage Response to DSBs by Post-Translational Modifications
Current Genomics Statin Intolerance: Why and What to do – With a Focus on Diabetic People
Current Medicinal Chemistry The Influence of Endothelial Nitric Oxide Synthase (eNOS) Genetic Polymorphisms on Cholesterol Blood Levels Among Type 2 Diabetic Patients on Atorvastatin Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets HIV Infection and Myocardial Infarction
Current HIV Research Current Scenario of 1,4-Diazepines as Potent Biomolecules-A Mini Review
Mini-Reviews in Medicinal Chemistry Identifying Risk Factors for Clinically Significant Diabetic Macula Edema in Patients with Type 2 Diabetes Mellitus
Current Diabetes Reviews Orthopedic Aspects of the Diabetic Foot
Current Pharmaceutical Design Biomarkers of Oxidative Stress and the Relationship to Cigarette Smoking
Mini-Reviews in Organic Chemistry